- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07826650
The Impact of Acute Pain on Sleep Parameters in the Insomnia Population and Healthy Controls
The Impact of Acute Pain on Sleep Parameters in the Insomnia Population and Healthy Controls: a Case-control Study
This study investigates how acute exercise-induced muscular pain affects sleep quality and sleep architecture in people with insomnia compared to healthy sleepers.
Sleep disturbances and pain often influence each other, creating a negative cycle; however, it remains unclear how acute muscle pain-such as delayed-onset muscle soreness (DOMS) after strenuous exercise-alters continuous sleep parameters and pain sensitivity differently in clinical insomnia populations versus healthy controls.
Participants will be divided into two groups: individuals with clinical insomnia and age- and sex-matched healthy sleepers. Both groups will undergo a standardised exercise protocol designed to safely induce temporary, acute muscular soreness (DOMS). Objective sleep parameters (measured via wrist actigraphy) and subjective sleep parameters (measured via sleep diaries), will be monitored before and after the pain induction. The primary goal is to determine whether individuals with insomnia experience greater sleep disruption and altered pain recovery trajectories following an acute painful event compared to healthy individuals.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Leo Guohui Lin
- Phone Number: +852 94267004
- Email: guohui-leo.lin@connect.polyu.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- The Hong Kong Polytechnic University
-
Contact:
- Leo Guohui Lin
- Phone Number: +852 94267004
- Email: guohui-leo.lin@connect.polyu.hk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults aged 18 to 60 years
- Right-hand and right-foot dominant
Exclusion Criteria:
- History of any chronic musculoskeletal pain or presence of existing pain during recruitment
- Previous major injuries or surgery involving the lower limbs
- Sleep disorders other than insomnia
- Clinically diagnosed psychiatric disorders
- Contraindications to vigorous exercise identified through the physical activity readiness questionnaire (PAR-Q)
- Work night shifts or rotating shift schedules
- Pregnant
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Insomnia
|
Eccentric hamstring exercise
|
|
Healthy contry
|
Eccentric hamstring exercise
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sleep diary: Total Sleep Time
Time Frame: Day 0 to Day 14
|
Assessed using a daily consensus sleep diary.
Total Sleep Time is calculated as the total time spent asleep, derived from the total time in bed (bedtime to wake time) minus sleep onset latency and wake after sleep onset.
Higher values indicate longer sleep duration.
|
Day 0 to Day 14
|
|
Sleep diary: Sleep Onset Latency (SOL)
Time Frame: Day 0 to Day 14
|
Assessed using a daily consensus sleep diary.
Sleep Onset Latency is the estimated time (in minutes) it takes to fall asleep after turning off the lights.
Lower values indicate better sleep onset.
|
Day 0 to Day 14
|
|
Sleep diary: Wake After Sleep Onset (WASO)
Time Frame: Day 0 to Day 14
|
Assessed using a daily consensus sleep diary.
WASO is calculated as the total duration of wakefulness (in minutes) between initial sleep onset and final awakening, derived from the number of night awakenings multiplied by their average duration.
Lower values indicate better sleep continuity.
|
Day 0 to Day 14
|
|
Sleep diary: Sleep Efficiency (SE)
Time Frame: Day 0 to Day 14
|
Assessed using a daily consensus sleep diary.
Sleep Efficiency is calculated as the percentage of time in bed spent asleep: [(Total Sleep Time / Total Time in Bed) × 100].
Total Sleep Time is derived from total time in bed (time between bedtime and rise time) minus sleep onset latency and nocturnal wakefulness (calculated from the number and duration of night awakenings).
Scores range from 0% to 100%, with higher percentages indicating better sleep quality.
|
Day 0 to Day 14
|
|
Actigraphy: Total Sleep Time (TST)
Time Frame: Day 0 to Day 14
|
Measured objectively using a wrist-worn ActiGraph accelerometer and validated sleep-scoring algorithms.
Total Sleep Time is defined as the total amount of time spent sleeping between bedtime and rise time.
Higher values indicate longer sleep duration.
|
Day 0 to Day 14
|
|
Actigraphy: Sleep Onset Latency (SOL)
Time Frame: Day 0 to Day 14
|
Measured objectively using a wrist-worn ActiGraph accelerometer.
Sleep Onset Latency is the time (in minutes) between the initial bedtime (lights out) and the onset of continuous sleep detected by the algorithm.
Lower values indicate faster sleep onset and better sleep initiation.
|
Day 0 to Day 14
|
|
Actigraphy: Wake After Sleep Onset (WASO)
Time Frame: Day 0 to Day 14
|
Measured objectively using a wrist-worn ActiGraph accelerometer.
WASO is defined as the total number of minutes spent awake after initial sleep onset and before final awakening, as determined by epoch-by-epoch movement counts.
Lower values indicate better sleep continuity and fewer night awakenings.
|
Day 0 to Day 14
|
|
Actigraphy: Sleep Efficiency (SE)
Time Frame: Day 0 to Day 14
|
Measured objectively using a wrist-worn ActiGraph accelerometer.
Sleep Efficiency is calculated as the percentage of time in bed spent asleep: [(Total Sleep Time / Total Time in Bed) × 100].
Values range from 0% to 100%, with higher percentages indicating better sleep quality and efficiency.
|
Day 0 to Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle damage severity: Muscle pain
Time Frame: Day 0 to Day 14
|
Muscle pain will be measured by an 11-point NRS, with 0 represents "no pain" and 10 indicating "worst imaginable pain".
The Outcome will be recorded at rest, reach for the floor with knees straight, and during a validated hamstring provocative manoeuvre, the "taking-off shoe" test.
|
Day 0 to Day 14
|
|
Muscle damage severity: Muscle soreness
Time Frame: Day 0 to Day 14
|
Muscle soreness will be measured by an 7-point Likert scale, with 0= A complete absence of soreness," 1 = "A light soreness in the muscle felt only when touched/a vague ache," 2 = "A moderate soreness felt only when touched/a slight persistent pain," 3 = "A light muscle soreness when walking up and down stairs," 4 = "A light muscle soreness when walking on flat surface," 5 = "A moderate muscle soreness, stiffness, or weakness when walking," 6 = "A severe muscle soreness, stiffness, or weakness that limits my ability to move."
|
Day 0 to Day 14
|
|
Sleep Questionnaires: the Insomnia Severity Index (ISI)
Time Frame: Day 0 and Day 7
|
The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia.
Each item is rated on a 5-point Likert scale (0 to 4).
The total score ranges from 0 to 28, with higher scores indicating greater severity of insomnia
|
Day 0 and Day 7
|
|
Sleep Questionnaires: The Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Day 0 and Day 7
|
The PSQI is a 19-item self-report questionnaire that evaluates sleep quality and disturbances over a 1-month time interval.
It generates seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction.
Each component is scored from 0 to 3. The sum of these seven component scores yields a global PSQI score ranging from 0 to 21, where higher scores indicate poorer sleep quality.
|
Day 0 and Day 7
|
|
Psychological measurement: Depression, Anxiety, and Stress Scale (DASS-21)
Time Frame: Day 0, Day 7, and Day 9
|
Assessed using the 21-item Depression Anxiety Stress Scales (DASS-21).
The instrument consists of three 7-item subscales measuring depression, anxiety, and stress.
Each item is rated on a 4-point Likert scale ranging from 0 ("did not apply to me at all") to 3 ("applied to me very much or most of the time").
Sum scores for each subscale are calculated and multiplied by 2 to yield total scores ranging from 0 to 42 for each dimension (Depression: 0-42, Anxiety: 0-42, Stress: 0-42), with a total overall score ranging from 0 to 126.
Higher scores indicate greater levels of psychological distress/severity.
|
Day 0, Day 7, and Day 9
|
|
Psychological measurement: Pain Catastrophizing Scale (PCS)
Time Frame: Day 0, Day 7, and Day 9
|
Assessed using the 13-item Pain Catastrophizing Scale (PCS) to evaluate catastrophic thoughts and feelings associated with pain (comprising rumination, magnification, and helplessness subscales).
Each item is rated on a 5-point Likert scale from 0 ("not at all") to 4 ("all the time").
The total score ranges from 0 to 52, with higher scores indicating higher levels of pain catastrophizing.
|
Day 0, Day 7, and Day 9
|
|
Psychological measurement: Fear of Pain Questionnaire (FPQ-9)
Time Frame: Day 0, Day 7, and Day 9
|
Assessed using the 9-item short form of the Fear of Pain Questionnaire (FPQ-9) to assess fear of different painful experiences across severe pain, minor pain, and medical pain domains.
Each item is rated on a 5-point Likert scale from 1 ("not at all") to 5 ("extreme").
The total score ranges from 9 to 45, with higher scores indicating greater fear of pain.
|
Day 0, Day 7, and Day 9
|
|
Psychological measurement: Tampa Scale for Kinesiophobia (TSK-11)
Time Frame: Day 0, Day 7, and Day 9
|
Assessed using the 11-item Tampa Scale for Kinesiophobia (TSK-11) to evaluate fear of movement or (re)injury.
Each item is scored on a 4-point Likert scale ranging from 1 ("strongly disagree") to 4 ("strongly agree").
The total score ranges from 11 to 44, with higher scores indicating greater fear of movement/kinesiophobia.
|
Day 0, Day 7, and Day 9
|
|
Physical Activity Level: International Physical Activity Questionnaire - Short Form (IPAQ-SF)
Time Frame: Day 0 and Day 7
|
Assessed using the 7-item International Physical Activity Questionnaire - Short Form (IPAQ-SF).
The questionnaire measures the duration (minutes) and frequency (days) of walking, moderate-intensity activities, and vigorous-intensity activities performed over the last 7 days.
Total physical activity volume is calculated as MET-minutes per week (MET-min/week) using standardised MET energy expenditure values: Walking = 3.3 METs, Moderate PA = 4.0 METs, and Vigorous PA = 8.0 METs.
Total score is the sum of (METs × minutes × days) across all three domains, starting at 0 with no strict upper limit.
Higher scores indicate higher levels of overall physical activity.
|
Day 0 and Day 7
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Musculoskeletal Diseases
- Nervous System Diseases
- Muscular Diseases
- Mental Disorders
- Sleep Wake Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Musculoskeletal Pain
- Sleep Initiation and Maintenance Disorders
Other Study ID Numbers
- Pain-Sleep-2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.